HSGX 1,00$ (-64%)

• MK 29 Mio. $
  
• Cash 9 Mio. $
  
• negatives EK
  
• lohnt nicht
  

www.massdevice.com/...es-on-missed-endpoint-in-neocart-trial/

siehe Posting # 1

--> lohnt nicht

Kapitalerhöhung im Anmarsch

ir.histogenics.com/...77&p=irol-newsArticle&ID=2370348

17 Mio. $ Offering

"WALTHAM, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation, a leader in the development of restorative cell therapies, today announced the pricing of an underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant. The gross proceeds to Histogenics from this offering are expected to be $17.0 million, before deducting underwriting discounts and commissions, and offering expenses payable by Histogenics.  The warrants are exercisable immediately upon issuance at a price of $0.70 per share of common stock and have a term of five years commencing on the date of issuance. The offering is expected to close on or about October 10, 2018, subject to customary closing conditions."

ir.histogenics.com/...77&p=irol-newsArticle&ID=2370442

• MK 27 Mio. $
  
• Cash 5 Mio. $
  
• Cash-burn ~ 7 Mio. in Q3
  
• Finger weg!
  

ir.histogenics.com/news-releases/...ird-quarter-2018-financial

FDA fordert eine zusätzliche klinische Studie

• MK 7,5 Mio. $
  
• Finger weg!
  

ir.histogenics.com/news-releases/...ussions-regarding-neocartr